Early granulomatous foreign body reactions to a novel alginate dermal filler: the system's failure?
Abstract
[BACKGROUND] Cutaneous granulomas after a soft filler injection represent one of the worst scenarios for both patient and injector.
[OBJECTIVES] To present clinical and histopathological features of granulomatous nodular reactions induced by a new alginate-based dermal filler (Novabel(®)), and put it in context of the process of injectable soft tissue fillers approval and promotion in the EU.
[METHODS] A case series of four patients injected with Novabel(®) for volume restoration of the face and hands, who developed severe foreign body reactions.
[RESULTS] Four patients injected with Novabel(®) into tear troughs and/or dorsa of hands developed severe granulomatous reactions within months after injections. As we injected with the new filler into a total of 10 patients, a high incidence of 40% of the disfiguring adverse effect was observed. The inadequate response of manufacturer to our reporting the side-effects along with the available data on registration process of dermal fillers confirmed that the area is not well-regulated.
[CONCLUSIONS] The status of dermal fillers as class III medical devices, and the process of their approval and marketing in the EU need to be seriously reconsidered to avoid unnecessary and serious adverse reactions.
[OBJECTIVES] To present clinical and histopathological features of granulomatous nodular reactions induced by a new alginate-based dermal filler (Novabel(®)), and put it in context of the process of injectable soft tissue fillers approval and promotion in the EU.
[METHODS] A case series of four patients injected with Novabel(®) for volume restoration of the face and hands, who developed severe foreign body reactions.
[RESULTS] Four patients injected with Novabel(®) into tear troughs and/or dorsa of hands developed severe granulomatous reactions within months after injections. As we injected with the new filler into a total of 10 patients, a high incidence of 40% of the disfiguring adverse effect was observed. The inadequate response of manufacturer to our reporting the side-effects along with the available data on registration process of dermal fillers confirmed that the area is not well-regulated.
[CONCLUSIONS] The status of dermal fillers as class III medical devices, and the process of their approval and marketing in the EU need to be seriously reconsidered to avoid unnecessary and serious adverse reactions.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | dermal filler
|
필러 주입술 | dict | 2 | |
| 시술 | filler
|
필러 주입술 | dict | 2 |
MeSH Terms
Adult; Alginates; Cellulose; Cosmetic Techniques; Dermatologic Agents; Esthetics; Female; Follow-Up Studies; Foreign-Body Reaction; Glucuronic Acid; Granuloma, Foreign-Body; Hexuronic Acids; Humans; Injections, Subcutaneous; Lactic Acid; Mannitol; Middle Aged; Risk Assessment; Sampling Studies; Skin Aging; Time Factors; Treatment Outcome
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Penetrating globe injury following periocular hyaluronic acid filler injection: A case report.
- Choroidal ischemia after self-injection of hyaluronic acid filler.
- Intra-articular therapies for synovial joint dysfunction: a comprehensive integrative review.
- Clinical safety of a low-modification hyaluronic acid filler (MoD 2%) for facial rejuvenation.
- A Fibrous-Porous Microsphere-Based Composite Filler for Synchronized Immediate and Long-Term Soft Tissue Restoration.